Conexeu Sciences (NASDAQ:CNXU) Stock Jumps 3.1% – Here’s Why

Conexeu Sciences Inc. (NASDAQ:CNXU)’s share price traded up 3.1% on Monday. The stock traded as high as $2.40 and last traded at $2.33. Approximately 219,846 shares traded hands during trading, a decline of 46% from the average session volume of 404,472 shares. The stock had previously closed at $2.26.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Conexeu Sciences from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, November 2nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.00.

Conexeu Sciences Price Performance

The stock has a fifty day simple moving average of $3.61.

Conexeu Sciences (NASDAQ:CNXU) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). Equities analysts expect that Conexeu Sciences Inc. will post -0.40 EPS for the current fiscal year.

Insider Buying and Selling at Conexeu Sciences

In related news, Director Lynn Sebastian Purcell purchased 166,666 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were bought at an average cost of $3.00 per share, with a total value of $499,998.00. Following the acquisition, the director owned 3,118,514 shares of the company’s stock, valued at $9,355,542. This represents a 5.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.